Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
Despite a flat start to 2026, Nvidia's valuation appears compelling as new forecasts project global AI spending to surge past $3.3 trillion by 2027, suggesting the chipmaker's growth story is far from over.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
A detailed four-month audit of every expense left one individual perplexed: despite a solid income and no major debt, their bank account was perpetually near empty. The experience underscores a critical gap between tracking spending and controlling it, a common pitfall in personal finance.
A deep dive into the intrinsic value of Aurelius Technologies Berhad (KLSE:ATECH) using a Discounted Cash Flow model suggests a potential disconnect between its market price and fundamental valuation, raising questions for investors.
